CN101495115A - 组合治疗 - Google Patents

组合治疗 Download PDF

Info

Publication number
CN101495115A
CN101495115A CNA200780028588XA CN200780028588A CN101495115A CN 101495115 A CN101495115 A CN 101495115A CN A200780028588X A CNA200780028588X A CN A200780028588XA CN 200780028588 A CN200780028588 A CN 200780028588A CN 101495115 A CN101495115 A CN 101495115A
Authority
CN
China
Prior art keywords
pyridylmethyl
xylylenediamine
tetrahydro
bis
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780028588XA
Other languages
English (en)
Chinese (zh)
Inventor
G·布里杰
L·M·佩鲁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN101495115A publication Critical patent/CN101495115A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA200780028588XA 2006-08-02 2007-08-02 组合治疗 Pending CN101495115A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83529006P 2006-08-02 2006-08-02
US60/835,290 2006-08-02

Publications (1)

Publication Number Publication Date
CN101495115A true CN101495115A (zh) 2009-07-29

Family

ID=38997866

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780028588XA Pending CN101495115A (zh) 2006-08-02 2007-08-02 组合治疗

Country Status (12)

Country Link
US (1) US20100003224A1 (https=)
EP (1) EP2068868A2 (https=)
JP (1) JP2009545620A (https=)
CN (1) CN101495115A (https=)
AR (1) AR063470A1 (https=)
AU (1) AU2007281090A1 (https=)
BR (1) BRPI0714799A2 (https=)
CA (1) CA2659463A1 (https=)
IL (1) IL196556A0 (https=)
MX (1) MX2009001272A (https=)
RU (1) RU2009107030A (https=)
WO (1) WO2008017025A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206085A (zh) * 2014-12-12 2017-09-26 联邦科学和工业研究组织 使用α 9 整联蛋白拮抗剂和CXCR4拮抗剂的HSC的迁移和释放
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
CN115737821A (zh) * 2016-04-08 2023-03-07 赛罗斯制药有限公司 用于治疗aml和mds的rara激动剂

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
WO2008075371A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
JP2013541520A (ja) * 2010-09-17 2013-11-14 アンチセンス・セラピューティックス・リミテッド 幹細胞および／または前駆細胞を動員するための方法
WO2012129073A2 (en) * 2011-03-18 2012-09-27 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
EP2720690A4 (en) * 2011-06-16 2014-12-31 Childrens Medical Center COMBINED CHEMICAL MODIFICATION OF SPHINGOSIN-1-PHOSPHATE (S1P) AND CXCR4 SIGNALING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND TRANSPLANT
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
ES2210255T3 (es) * 1993-06-08 2004-07-01 Smithkline Beecham Corporation Metodos para mejorar la actividad biologica de quimiocinas.
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
CN1081685C (zh) * 1994-08-19 2002-03-27 阿克佐诺贝尔公司 纤维素溶液及其制得的产品
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5968546A (en) * 1997-05-16 1999-10-19 Baur; Marcus Keratinocyte culture from precursor cells
NZ509199A (en) * 1998-05-28 2003-10-31 Biogen Inc A VLA-4 inhibitor: oMePUPA-V
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CZ2002518A3 (cs) * 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
AU2334301A (en) * 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6734191B2 (en) * 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
HK1052011A1 (zh) * 2000-09-15 2003-08-29 Anormed Inc. 趋化因子受体结合杂环化合物
DE60137435D1 (de) * 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
DE60136476D1 (de) * 2000-09-29 2008-12-18 Anormed Inc -stickstoffhaltigen zyklischen polyaminen und deren verbindungen
WO2004091518A2 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
JP4778420B2 (ja) * 2003-04-22 2011-09-21 アノーメッド インコーポレイティド 増強された有効性を有するケモカインレセプタ結合複素環式化合物
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
EP1730113B1 (en) * 2004-03-15 2016-12-28 Genzyme Corporation Process for the synthesis of a cxcr4 antagonist
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206085A (zh) * 2014-12-12 2017-09-26 联邦科学和工业研究组织 使用α 9 整联蛋白拮抗剂和CXCR4拮抗剂的HSC的迁移和释放
CN107206085B (zh) * 2014-12-12 2022-01-28 联邦科学和工业研究组织 使用α9整联蛋白拮抗剂和CXCR4拮抗剂的HSC的迁移和释放
CN115737821A (zh) * 2016-04-08 2023-03-07 赛罗斯制药有限公司 用于治疗aml和mds的rara激动剂
CN115737821B (zh) * 2016-04-08 2024-04-12 赛罗斯制药有限公司 用于治疗aml和mds的rara激动剂
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案

Also Published As

Publication number Publication date
AU2007281090A1 (en) 2008-02-07
WO2008017025A3 (en) 2008-10-09
EP2068868A2 (en) 2009-06-17
BRPI0714799A2 (pt) 2013-05-21
CA2659463A1 (en) 2008-02-07
US20100003224A1 (en) 2010-01-07
MX2009001272A (es) 2009-02-11
IL196556A0 (en) 2009-11-18
JP2009545620A (ja) 2009-12-24
RU2009107030A (ru) 2010-09-10
AR063470A1 (es) 2009-01-28
WO2008017025A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
CN101495115A (zh) 组合治疗
CN101500595A (zh) 组合治疗
KR100996378B1 (ko) 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
CN101365336B (zh) 增强化疗的方法
JP2008509928A (ja) 前駆／幹細胞を動員するためのケモカインの組み合わせ
ES2497092T3 (es) Procedimientos para el aumento del flujo sanguíneo y/o la estimulación de la regeneración de tejidos
HK40026817A (en) Methods to mobilize progenitor/stem cells
MX2008002374A (en) Methods to enhancechemotherapy
MX2007001802A (en) Chemokine combinations to mobilize progenitor/stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090729